Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling

Prog Neurobiol. 2015 Nov:134:161-77. doi: 10.1016/j.pneurobio.2015.09.009. Epub 2015 Sep 25.

Abstract

Human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) are two novel cell sources for studying neurodegenerative diseases. Dopaminergic neurons derived from hiPSCs/hESCs have been implicated to be very useful in Parkinson's disease (PD) research, including cell replacement therapy, disease modeling and drug screening. Recently, great efforts have been made to improve the application of hiPSCs/hESCs in PD research. Considerable advances have been made in recent years, including advanced reprogramming strategies without the use of viruses or using fewer transcriptional factors, optimized methods for generating highly homogeneous neural progenitors with a larger proportion of mature dopaminergic neurons and better survival and integration after transplantation. Here we outline the progress that has been made in these aspects in recent years, particularly during the last year, and also discuss existing issues that need to be addressed.

Keywords: Disease modeling; Dopaminergic differentiation; Induced pluripotent stem cells; Neural transplantation; Parkinson's disease; Reprogramming.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology
  • Drug Evaluation, Preclinical
  • Humans
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / physiology*
  • Induced Pluripotent Stem Cells / transplantation*
  • Parkinson Disease / genetics
  • Parkinson Disease / physiopathology*
  • Parkinson Disease / therapy*

Substances

  • Antiparkinson Agents